HR 2427

To amend the Federal Food, Drug, and Cosmetic Act with respect to advisory committee process.

Congress: 114 (2015–2017, Ended)
Chamber: House
Policy Area: Health
Introduced: May 19, 2015
Current Status: Referred to the Subcommittee on Health.
Latest Action: Referred to the Subcommittee on Health. (May 22, 2015)
Official Text: https://www.congress.gov/bill/114th-congress/house-bill/2427

Sponsor

Name: Rep. Shimkus, John [R-IL-15]
Party: Republican • **State:** IL • **Chamber:** House

Cosponsors

No cosponsors are listed for this bill.

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	May 22, 2015

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
114 S 2737	Related bill	**Mar 17, 2016:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
114 HR 6	Related bill	**Jul 13, 2015:** Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary (as of May 19, 2015)

This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to provide an opportunity for a person whose premarket submission for a medical device is subject to review by a classification panel to provide recommendations on the expertise needed among the members of the panel.

The FDA must consider these recommendations and ensure that panels include at least two members with expertise clinically relevant to the device and at least one member who is knowledgeable about the technology of the device. The person whose device is under review may designate a representative (who may be accompanied by experts) to participate in panel meetings.

Actions Timeline

- **May 22, 2015:** Referred to the Subcommittee on Health.
- **May 19, 2015:** Introduced in House
- **May 19, 2015:** Referred to the House Committee on Energy and Commerce.